Frontiers | Could Azithromycin Be Part of Pseudomonas aeruginosa Acute Pneumonia Treatment?
Overusing antibiotics? Find out with Antibiotic Footprint Calculator — Centre for Tropical Medicine and Global Health
Current accounts of antimicrobial resistance: stabilisation, individualisation and antibiotics as infrastructure | Humanities and Social Sciences Communications
The endosymbiont Wolbachia rebounds following antibiotic treatment | PLOS Pathogens
The endosymbiont Wolbachia rebounds following antibiotic treatment | PLOS Pathogens
Life After C. diff | CDC
Paxlovid rebound happens. Why and to whom are still a mystery - STAT
HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs - ScienceDirect
Toward a Comprehensive Strategy to Mitigate Dissemination of Environmental Sources of Antibiotic Resistance | Environmental Science & Technology
Surge in infections leads to global shortage of antibiotics | Financial Times
What Is Paxlovid Rebound, and How Common Is It? - Scientific American
Gut microbiome signatures and host colonization with multidrug-resistant bacteria: Trends in Microbiology
A Critical, Nonlinear Threshold Dictates Bacterial Invasion and Initial Kinetics During Influenza | Scientific Reports
Antibiotics | Free Full-Text | Impact of a Primary Care Antimicrobial Stewardship Program on Bacterial Resistance Control and Ecological Imprint in Urinary Tract Infections
Global Survey of Antibiotic Resistance Genes in Air | Environmental Science & Technology
How does COVID-19 rebound after Paxlovid treatment differ between the BA.5 and BA.2.12.1 subvariants?
Paxlovid: Covid-19 rebound seen in some people after taking the Pfizer drug | New Scientist
What Are COVID Rebound and Paxlovid Rebound? | Everyday Health
Removal of Antibiotics from Aqueous Solutions by a Carbon Adsorbent Derived from Protein-Waste-Doped Biomass | ACS Omega
COVID-19 rebound found uncommon after antiviral treatment | CIDRAP
Bacterial infections linked to one in eight global deaths, according to GRAM study — Centre for Tropical Medicine and Global Health
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study - The Lancet Infectious Diseases
Pfizer (PFE) Told by FDA to Test Repeat Paxlovid Course for Rebound Patients - Bloomberg
